Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
MacroGenics, Inc. (Nasdaq: MGNX) is a biopharmaceutical company that publicly describes its focus as discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The MGNX news page on Stock Titan aggregates company-issued updates and third-party coverage so readers can follow how MacroGenics communicates progress across its oncology pipeline, technology platforms and collaborations.
In its press releases, MacroGenics highlights clinical developments for programs such as lorigerlimab, a bispecific PD‑1 × CTLA‑4 DART® molecule, and a portfolio of antibody-drug conjugates including MGC026, MGC028 and MGC030. News items also describe partnered programs like MGD024 with Gilead Sciences, ZYNYZ® (retifanlimab-dlwr) with Incyte and TZIELD® (teplizumab-mzwv) associated with Sanofi, including milestone structures and royalty arrangements disclosed by the company.
MacroGenics regularly issues announcements on quarterly financial results, cash runway expectations, royalty purchase agreements and other financing-related transactions. Additional news covers participation in healthcare and investment conferences, leadership changes such as the appointment of a new President and Chief Executive Officer, and updates on strategic priorities for advancing its antibody-based oncology portfolio and technology platforms.
Investors and observers who follow MGNX news can use this page to review how MacroGenics reports progress in its clinical trials, describes its collaborations and outlines its financial position in official communications. Bookmarking the news feed provides a centralized view of press releases and related information that the company files or references in its SEC disclosures.
MacroGenics, Inc. (NASDAQ: MGNX) has promoted Eric Risser to Chief Operating Officer, effective February 22, 2022. Risser has been with the company since 2009, significantly contributing to collaboration partnerships, business development, and program management. He previously served as Senior Vice President and Chief Business Officer. The promotion reflects the company's confidence in his leadership abilities to drive product advancements and shareholder value. MacroGenics focuses on developing innovative antibody-based therapeutics for cancer treatment, leveraging advanced technology platforms.
MacroGenics, Inc. (MGNX) has launched a Phase 1 dose escalation study of MGC018 in combination with lorigerlimab, focusing on B7-H3-directed therapies for treating solid tumors. The company plans to meet the FDA to discuss a registration-directed study for MGC018 in metastatic castration-resistant prostate cancer (mCRPC). Financially, MacroGenics reported $77.4 million in revenue for 2021, a decline from $104.9 million in 2020. The net loss widened to $202.1 million, compared to $129.7 million in the previous year. The company maintains a cash runway through 2023.
MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapeutics for cancer, will release its fourth quarter financial results for 2021 on February 24, 2022, after the market closes. The company will host a conference call at 4:30 PM ET on the same day to discuss the results and corporate progress. Investors can access the call by dialing (877) 303-6253 domestically or (973) 409-9610 internationally, with a Conference ID of 1067087. A webcast will also be available on the company's website.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focusing on monoclonal antibody-based therapies for cancer, will participate in several upcoming virtual conferences in February 2022. Notable events include:
- Guggenheim Healthcare Talks on February 10, 2022, at 9:00 am ET.
- Citi’s 2022 Virtual Immuno-Oncology Summit on February 17, 2022, at 12:30 pm ET.
- 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 10:40 am ET.
Archived webcasts will be available on MacroGenics' website.
MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company, announced its participation in several healthcare conferences in November and December 2021. Key events include:
- Credit Suisse 30th Annual Healthcare Conference: November 9, 2021, at 8:00 am ET.
- Stifel 2021 Virtual Healthcare Conference: November 16, 2021, at 8:00 am ET.
- Evercore ISI HealthCONx Virtual Conference: December 2, 2021, at 8:25 am ET.
- JMP Securities Hematology and Oncology Summit: December 6, 2021, at 1:00 pm ET.
Webcasts of these presentations will be available on their website.
MacroGenics, Inc. (NASDAQ: MGNX) has submitted an IND application for MGD024, a bispecific DART molecule targeting CD123 and CD3 for AML. The FDA approved its GMP manufacturing facility for MARGENZA drug substance. However, enrollment for Cohort A of the Phase 2/3 MAHOGANY study of margetuximab is being discontinued. Financial results for Q3 2021 revealed total revenue of $15.7 million, down from $18.3 million in Q3 2020. R&D expenses rose to $49.8 million, leading to a net loss of $52.9 million. The company expects its cash position to fund operations through 2023.
MacroGenics, Inc. (Nasdaq: MGNX) will release its third-quarter 2021 financial results after the market closes on November 2, 2021. A conference call to discuss these results and recent corporate developments will be held on the same date at 4:30 pm ET. Investors can join the call by dialing the appropriate access numbers five minutes prior to the start. The presentation will also be available via a listen-only webcast on the company's Investor Relations website, with a recorded replay accessible for 30 days post-call.
MacroGenics announced promising interim results from Part 1 of the Phase 2/3 MAHOGANY clinical trial for margetuximab, targeting HER2+ gastric cancer. Out of 40 evaluated patients, 21 achieved confirmed responses, exceeding the trial's futility boundaries. The combination therapy demonstrated a 78% tumor shrinkage rate and a median response duration of 10.3 months. The treatment was well tolerated, with only 19% experiencing Grade 3 adverse events. These findings support advancing to Part 2 of the trial, with potential implications for first-line treatment options.
MacroGenics (NASDAQ: MGNX) announced preliminary safety and anti-tumor results from the Phase 1 trial of MGC018, an investigational antibody-drug conjugate. In metastatic castration-resistant prostate cancer (mCRPC), 54% of patients showed ≥ 50% PSA reduction, while 63% of evaluable patients displayed anti-tumor activity. In non-small cell lung cancer (NSCLC), 81% of evaluable patients had anti-tumor activity. The treatment demonstrated a manageable safety profile with only 7% discontinuation due to treatment-related adverse events. Further updates on other cohorts are anticipated.
On September 12, 2021, MacroGenics (Nasdaq: MGNX) announced multiple poster presentations for its investigational product candidates at the ESMO Virtual Conference scheduled for September 16-21, 2021. Key presentations include preliminary results for MGC018, an antibody-drug conjugate targeting advanced solid tumors, and data from the MAHOGANY trial on margetuximab in HER2+, PD-L1+ gastroesophageal adenocarcinoma. The posters will be accessible on the ESMO website and MacroGenics' investor relations page.